Center Laboratories, Inc. (4123.TWO)
TWD 34.9
(-0.43%)
TWD 34.9
(-0.43%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.62 Billion TWD | 61.9% |
| 2022 | 3.47 Billion TWD | -34.11% |
| 2021 | 5.27 Billion TWD | 39.94% |
| 2020 | 3.76 Billion TWD | -13.83% |
| 2019 | 4.37 Billion TWD | 52.6% |
| 2018 | 2.86 Billion TWD | -76.86% |
| 2017 | 12.37 Billion TWD | 39.6% |
| 2016 | 8.86 Billion TWD | 0.74% |
| 2015 | 8.8 Billion TWD | 294.41% |
| 2014 | 2.23 Billion TWD | 4565.71% |
| 2013 | 47.83 Million TWD | -62.18% |
| 2012 | 126.5 Million TWD | -46.42% |
| 2011 | 236.08 Million TWD | 476.99% |
| 2010 | 40.91 Million TWD | -56.43% |
| 2009 | 93.91 Million TWD | -69.76% |
| 2008 | 310.57 Million TWD | 362.44% |
| 2007 | 67.15 Million TWD | -49.76% |
| 2006 | 133.67 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.3 Billion TWD | 12.12% |
| 2024 Q2 | 6.31 Billion TWD | 0.19% |
| 2023 Q1 | 4.19 Billion TWD | 20.89% |
| 2023 Q3 | 6.02 Billion TWD | 3.98% |
| 2023 Q4 | 5.62 Billion TWD | -6.67% |
| 2023 FY | 5.62 Billion TWD | 61.9% |
| 2023 Q2 | 5.79 Billion TWD | 38.0% |
| 2022 Q2 | 1.84 Billion TWD | -48.16% |
| 2022 Q4 | 3.47 Billion TWD | 6.63% |
| 2022 FY | 3.47 Billion TWD | -34.11% |
| 2022 Q1 | 3.56 Billion TWD | -32.4% |
| 2022 Q3 | 3.25 Billion TWD | 76.34% |
| 2021 Q4 | 5.27 Billion TWD | 12.11% |
| 2021 FY | 5.27 Billion TWD | 39.94% |
| 2021 Q1 | 3.86 Billion TWD | 2.65% |
| 2021 Q2 | 4.54 Billion TWD | 17.45% |
| 2021 Q3 | 4.7 Billion TWD | 3.53% |
| 2020 Q3 | 3.24 Billion TWD | 93.75% |
| 2020 Q4 | 3.76 Billion TWD | 16.17% |
| 2020 Q2 | 1.67 Billion TWD | -56.7% |
| 2020 Q1 | 3.86 Billion TWD | -11.58% |
| 2020 FY | 3.76 Billion TWD | -13.83% |
| 2019 FY | 4.37 Billion TWD | 52.6% |
| 2019 Q3 | 4.72 Billion TWD | -15.64% |
| 2019 Q2 | 5.6 Billion TWD | 43.77% |
| 2019 Q1 | 3.89 Billion TWD | 36.08% |
| 2019 Q4 | 4.37 Billion TWD | -7.54% |
| 2018 Q2 | 3.3 Billion TWD | -75.23% |
| 2018 Q1 | 13.36 Billion TWD | 7.93% |
| 2018 FY | 2.86 Billion TWD | -76.86% |
| 2018 Q4 | 2.86 Billion TWD | -23.11% |
| 2018 Q3 | 3.72 Billion TWD | 12.56% |
| 2017 Q3 | 10.81 Billion TWD | 5.72% |
| 2017 Q2 | 10.22 Billion TWD | 12.13% |
| 2017 Q1 | 9.12 Billion TWD | 2.87% |
| 2017 FY | 12.37 Billion TWD | 39.6% |
| 2017 Q4 | 12.37 Billion TWD | 14.48% |
| 2016 Q3 | 9.13 Billion TWD | 3.25% |
| 2016 FY | 8.86 Billion TWD | 0.74% |
| 2016 Q1 | 9.36 Billion TWD | 6.41% |
| 2016 Q2 | 8.85 Billion TWD | -5.5% |
| 2016 Q4 | 8.86 Billion TWD | -2.97% |
| 2015 Q4 | 8.8 Billion TWD | -11.6% |
| 2015 FY | 8.8 Billion TWD | 294.41% |
| 2015 Q3 | 9.95 Billion TWD | 73.91% |
| 2015 Q2 | 5.72 Billion TWD | 91.85% |
| 2015 Q1 | 2.98 Billion TWD | 33.73% |
| 2014 Q1 | 58.06 Million TWD | 21.39% |
| 2014 FY | 2.23 Billion TWD | 4565.71% |
| 2014 Q4 | 2.23 Billion TWD | 170.66% |
| 2014 Q3 | 824.62 Million TWD | 1107.7% |
| 2014 Q2 | 68.28 Million TWD | 17.59% |
| 2013 Q2 | 208.76 Million TWD | -4.31% |
| 2013 Q3 | 48.41 Million TWD | -76.81% |
| 2013 FY | 47.83 Million TWD | -62.18% |
| 2013 Q4 | 47.83 Million TWD | -1.2% |
| 2013 Q1 | 218.15 Million TWD | 72.45% |
| 2012 Q2 | 245.8 Million TWD | -2.52% |
| 2012 Q4 | 126.5 Million TWD | -43.13% |
| 2012 Q3 | 222.45 Million TWD | -9.5% |
| 2012 Q1 | 252.15 Million TWD | 6.81% |
| 2012 FY | 126.5 Million TWD | -46.42% |
| 2011 Q3 | 131.32 Million TWD | -2.21% |
| 2011 Q1 | 155.73 Million TWD | 280.61% |
| 2011 Q2 | 134.29 Million TWD | -13.77% |
| 2011 Q4 | 236.08 Million TWD | 79.77% |
| 2011 FY | 236.08 Million TWD | 476.99% |
| 2010 FY | 40.91 Million TWD | -56.43% |
| 2010 Q4 | 40.91 Million TWD | 0.0% |
| 2009 FY | 93.91 Million TWD | -69.76% |
| 2008 FY | 310.57 Million TWD | 362.44% |
| 2007 FY | 67.15 Million TWD | -49.76% |
| 2006 FY | 133.67 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Allied Biotech Corporation | 796.6 Million TWD | -605.948% |
| GeneFerm Biotechnology Co., Ltd. | 152.07 Million TWD | -3597.837% |
| Easywell Biomedicals, Inc. | 386.34 Million TWD | -1355.607% |
| TTY Biopharm Company Limited | 1.91 Billion TWD | -193.656% |
| Synmosa Biopharma Corporation | 2.43 Billion TWD | -130.49% |
| Orient EuroPharma Co., Ltd. | 4.84 Billion TWD | -16.132% |
| Tien Liang BioTech Co., Ltd. | 84.65 Million TWD | -6542.689% |
| Orient Pharma Co., Ltd. | 716.92 Million TWD | -684.408% |
| InnoPharmax Inc. | 21.49 Million TWD | -26057.654% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 160.83 Million TWD | -3396.611% |
| Excelsior Biopharma Inc. | 377.4 Million TWD | -1390.079% |
| DV Biomed Co., Ltd. | 387.69 Million TWD | -1350.527% |
| Foresee Pharmaceuticals Co., Ltd. | 228.25 Million TWD | -2363.729% |
| Handa Pharmaceuticals, Inc. | 13.24 Million TWD | -42374.577% |
| UniPharma Co., Ltd. | 277 Thousand TWD | -2030092.78% |
| Anxo Pharmaceutical Co., Ltd. | 787.84 Million TWD | -613.804% |
| Alar Pharmaceuticals Inc. | 1.4 Million TWD | -399022.356% |
| Winston Medical Supply Co., Ltd. | 107.32 Million TWD | -5139.622% |
| Mercury Biopharmaceutical Corporation | 42.34 Million TWD | -13179.26% |
| Bioray Biotech Co., Ltd | 69.79 Million TWD | -7957.706% |
| TSH Biopharm Corporation Limited | 7.84 Million TWD | -71602.588% |